Clarity Pharmaceuticals Quarterly Activities and Financial Update
Key points
- Well funded with $152.9 million in cash as of September 30, 2026
- Phase III CLARIFY trial completed recruitment, topline data expected in H1 2027
- SECuRE trial achieved recruitment target, strong efficacy and safety profile observed
- Michelle Hickey joins as SVP of Targeted Copper Theranostic Commercial Operations
- Allison Rossiter joins the Board as an Independent Non-Executive Director
Full summary
Clarity Pharmaceuticals Ltd. has released its Quarterly Activity Report for the three months ending September 30, 2026. The company remains well funded with a cash position of $152.9 million, providing a strong balance sheet to support ongoing clinical trials. The registrational Phase III CLARIFY trial has completed recruitment and is in the patient follow-up phase, with topline data expected in the first half of 2027. The SECuRE trial, a Phase I/IIa theranostic trial, achieved its recruitment target and demonstrated substantial efficacy with 74% of evaluable participants achieving PSA25. Additionally, Clarity welcomed Michelle Hickey as Senior Vice President of Targeted Copper Theranostic Commercial Operations and Allison Rossiter as an Independent Non-Executive Director, enhancing the company's commercialization and board capabilities.
Summary generated by a large language model. Please interpret with care.